2016-06-30T11:18:19-05:00 2015-12-31 510229493 BARBACANE THORNTON & COMPANY LLP 200 SPRINGER BLDG 3411 SILVERSIDE RD WILMINGTON DE 198104866 990 2015-01-01 383569922 NEPHCURE KIDNEY INTERNATIONAL NEPH 8666374287 150 SOUTH WARNER ROAD NO 402 KING OF PRUSSIA PA 19406 IRVING SMOKLER PRESIDENT 8666374287 2016-06-30 JEFFREY A KOWALCZYK CPA P01563311 3024788940 2016-06-30 2015 2016-09-27 15:27:22Z IRVING SMOKLER 150 SOUTH WARNER ROAD NO 402 KING OF PRUSSIA PA 19406 3716873 0 X WWW.NEPHCURE.ORG X 2000 MI NEPHCURE KIDNEY INTERNATIONAL IS THE ONLY ORGANIZATION COMMITTED EXCLUSIVELY TO SUPPORTING RESEARCH SEEKING THE CAUSE OF THE POTENTIALLY DEBILITATING KIDNEY DISEASE OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) AND NEPHROTIC SYNDROME. THE ORGANIZATION IS COMMITTED TO IMPROVING TREATMENT AND FINDING A CURE FOR THIS DISEASE. 23 23 1 600 0 0 2763493 3010482 65000 0 1671 316 0 390625 2830164 3401423 609375 292388 0 0 1304728 1104096 0 0 294495 1294219 1320159 3208322 2716643 -378158 684780 1598383 1248942 1617589 583368 -19206 665574 X NEPHCURE KIDNEY INTERNATIONAL IS THE ONLY ORGANIZATION COMMITTED EXCLUSIVELY TO SUPPORTING RESEARCH SEEKING THE CAUSE OF THE POTENTIALLY DEBILITATING KIDNEY DISEASE OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) AND NEPHROTIC SYNDROME. THE ORGANIZATION IS COMMITTED TO IMPROVING TREATMENT AND FINDING A CURE FOR THIS DISEASE. 0 0 1015872 292388 RESEARCH - NEPHCURE KIDNEY INTERNATIONAL IS COMMITTED TO MULTI-YEAR GRANTS FOR BASIC, TRANSLATIONAL, AND CLINICAL SCIENTIFIC RESEARCH. THE PURPOSE OF THIS RESEARCH IS TO DETERMINE CAUSES OF KIDNEY DISEASE, FSGS & NEPHROTIC SYNDROME THAT COULD LEAD TO EFFECTIVE TREATMENTS 913018 HEALTH AND EDUCATION - NEPHCURE KIDNEY INTERNATIONAL FUNDS AND MANAGES PROGRAMS TO EDUCATE PATIENTS/FAMILIES ABOUT NEPHROTIC SYNDROME & FSGS. NEPHCURE KIDNEY INTERNATIONAL ALSO PROVIDES EDUCATION MATERIALS (BI-LINGUAL) FOR PHYSICIANS AND DIRECTLY TO PATIENT FAMILIES. 215753 ADVOCACY - NEPHCURE KIDNEY INTERNATIONAL WORKS WITH THE NATIONAL INSTITUTES OF HEALTH AND OTHER HEALTH FUNDING ORGANIZATIONS TO ENCOURAGE MORE RESEARCH INTO NEPHROTIC SYNDROME & FSGS. 2144643 1 1 0 1 0 1 0 0 0 0 1 0 0 0 0 1 1 0 0 0 1 1 0 0 1 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 11 0 1 1 1 0 1 CA 0 0 0 1 1 0 0 0 0 X 23 23 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 0 0 0 AL AK AZ AR CA CO CT FL GA KS KY IL LA ME MD MA MI MN MS MO NH NJ NM NY NC OK OH OR PA RI SC TN UT VA WV WA WI X THE ORGANIZATION 8666374287 150 SOUTH WARNER ROAD NO 402 KING OF PRUSSIA PA 19406 IRVING SMOKLER PRESIDENT 5.00 X X 0 0 0 RON COHEN VICE PRESIDENT 1.00 X X 0 0 0 ANDREW SILVERMAN TREASURER 3.00 X X 0 0 0 MICHAEL LEVINE VICE PRESIDENT 10.00 X X 0 0 0 CAROL SMOKLER SECRETARY 1.00 X X 0 0 0 ELAINE KAMIL CO-MEDICAL DIRECTOR 1.00 X 0 0 0 DANIEL KERSHAW CO-MEDICAL DIRECTOR 1.00 X 0 0 0 WILLIAM SMOYER CO-MEDICAL DIRECTOR 1.00 X 0 0 0 KATHLEEN BRODERICK MEMBER 5.00 X 0 0 0 CLAIRE CASCIO MEMBER 5.00 X 0 0 0 JIM DUQUETTE MEMBER 2.00 X 0 0 0 RICHARD FOSTER MEMBER 1.00 X 0 0 0 JENNIFER GEISSER MEMBER 1.00 X 0 0 0 SCOTT GOLDSTEIN MEMBER 1.00 X 0 0 0 STEPHEN HOLLOMAN MEMBER 2.00 X 0 0 0 PAUL MASS MEMBER 2.00 X 0 0 0 SARRETTA MCDONOUGH MEMBER 2.00 X 0 0 0 JOHN ROY MEMBER 1.00 X 0 0 0 JOSHUA ROY MEMBER 1.00 X 0 0 0 SONDRA STUBBLEFIELD MEMBER 1.00 X 0 0 0 CHARLES TURNER MEMBER 4.00 X 0 0 0 MANU VARMA MEMBER 1.00 X 0 0 0 CHRIS WHITNEY MEMBER 1.00 X 0 0 0 MARK STONE CEO/COO 40.00 X 115000 0 21153 HENRY BREHM FORMER EXECUTIVE DIRECTOR 40.00 X 257613 0 0 372613 0 21153 2 1 1 0 0 1874004 1136478 3010482 316 316 315450 1874004 315450 0 GAINS ON RESTRUCTURING 900099 390625 390625 390625 3401423 390625 0 316 254888 254888 37500 37500 136154 114369 1362 20423 893114 750216 8931 133967 9945 8354 99 1492 64883 54502 649 9732 18230 15156 2544 530 10726 8917 1497 312 58152 48346 8115 1691 221923 184501 30967 6455 34474 34474 270059 220382 46984 2693 197556 167922 9878 19756 69136 56692 2074 10370 67659 67013 646 29120 29120 7537 7537 9388 9388 10631 10631 TERMINATION COSTS 257613 54836 123698 79079 PATIENT FAMILY EDUCATIO 28581 28581 0 0 OTHER COSTS 26044 5544 12505 7995 RESEARCH COSTS 3330 3330 2716643 2144643 277505 294495 457739 709348 218507 0 840785 468245 31187 23747 60676 13074 50165 47602 1598383 1248942 16831 55380 946035 527988 29723 0 625000 0 1617589 583368 X -729501 -71275 710295 736849 -19206 665574 1598383 1248942 684780 0 X 0 1 X 0 0 X 2358766 2362438 3277656 2763493 1136478 11898831 2358766 2362438 3277656 2763493 1136478 11898831 11898831 4205 3314 2467 1671 316 11973 270091 374988 587260 390625 1622964 13533768 65000 0.87920 0.89960 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 58152 1 1 0 1 0 0 1 58152 0 0 58152 0 157516 1 0 60676 13074 47602 47602 X 3444044 42621 42621 3401423 0 3401423 2759264 42621 42621 2716643 0 2716643 PART X, LINE 2: THE ORGANIZATION IS EXEMPT FROM FEDERAL INCOME TAX UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE. HOWEVER, INCOME FROM CERTAIN ACTIVITIES NOT DIRECTLY RELATED TO THE ORGANIZATION'S TAX-EXEMPT PURPOSE MAY BE SUBJECT TO TAXATION AS UNRELATED BUSINESS INCOME. GENERALLY ACCEPTED ACCOUNTING PRINCIPLES PRESCRIBE RULES FOR THE RECOGNITION, MEASUREMENT, CLASSIFICATION, AND DISCLOSURE IN THE FINANCIAL STATEMENTS OF UNCERTAIN TAX POSITIONS TAKEN OR EXPECTED TO BE TAKEN IN THE ORGANIZATION'S TAX RETURNS. MANAGEMENT HAS DETERMINED THAT THE ORGANIZATION DOES NOT HAVE ANY UNCERTAIN TAX POSITIONS OR ASSOCIATED UNRECOGNIZED BENEFITS THAT MATERIALLY IMPACT THE FINANCIAL STATEMENTS OR RELATED DISCLOSURES. SINCE TAX MATTERS ARE SUBJECT TO SOME DEGREE OF UNCERTAINTY, THERE CAN BE NO ASSURANCE THAT THE ORGANIZATION'S TAX RETURNS WILL NOT BE CHALLENGED BY THE TAXING AUTHORITIES AND THAT THE ORGANIZATION WILL NOT BE SUBJECT TO ADDITIONAL TAX, PENALTIES, AND INTEREST AS A RESULT OF SUCH CHALLENGE. INCOME TAX RETURNS OF THE ORGANIZATION FOR 2013, 2014, AND 2015 ARE SUBJECT TO EXAMINATION BY TAX AUTHORITIES, GENERALLY FOR THREE YEARS AFTER THEY WERE FILED. 1 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 GRANT TO RECIPIENT IN THE REGION 37500 0 0 0 0 0 0 37500 0 37500 EUROPE RESEARCH 37500 CHECK 0 0 0 0 0 0 COUNTDOWN TO A CURE 640102 543762 96340 96340 WALKS 502941 476011 26930 26930 4 1042479 850299 192180 192180 2185522 1870072 315450 315450 315450 0 1 MASS GENERAL HOSPITAL 185 CAMBRIDGE ST BOSTON MA 02114 041564655 501(C)3 37500 YOUNG INVESTIGATOR RESEARCH GRANT RUSH UNIVERSITY MEDICAL CENTER 1700 WEST VAN BUREN ST 250 CHICAGO IL 60612 362174823 501(C)3 50000 ESTABLISHED INVESTIGATOR RESEARCH GRANT INNOLYST INC 180 WARREN RD SAN MATEO CA 94401 51388 REGISTRY GRANT THE TRUSTEES OF COLUMBIA UNIVERSITY 615 WEST 131ST ST 3RD FLOOR NEW YORK NY 10027 135598093 501(C)3 46000 CUREGN RESEARCH GRANT UNIVERSITY OF NORTH CAROLINA 7036-D BURNETT WOMACK BLDG CAMPUS BOX 7155 CHARLOTTE NC 275997155 566001393 501(C)3 70000 CUREGN RESEARCH GRANT 4 1 1 0 0 0 0 0 0 0 0 HENRY BREHM FORMER EXECUTIVE DIRECTOR 257613 0 0 0 0 0 0 0 0 0 257613 0 0 0 PART I, LINE 4A DURING THE YEAR 2014, THE ORGANIZATION WAS RESTRUCTURED AND THE EXECUTIVE DIRECTOR POSITION WAS ELIMINATED. AS A RESULT, HARRY BREHM'S EMPLOYMENT WAS TERMINATED. HARRY BREHM'S 2015 SALARY CONSISTS OF TERMINATION PAYMENTS OF $257,613. FORM 990, PART VI, SECTION A, LINE 2 TWO BOARD MEMBERS ARE RELATED BY MARRIAGE FORM 990, PART VI, SECTION B, LINE 11 A FINAL COPY OF FORM 990 IS PROVIDED TO EACH VOTING MEMBER OF THE GOVERNING BOARD. FORM 990, PART VI, SECTION B, LINE 12C THE BOARD REVIEWS COMPLETED CONFLICT OF INTEREST QUESTIONNAIRES AND DISCLOSES INFORMATION DURING THE ANNUAL BOARD MEETING FOR BOARD APPROVAL. FORM 990, PART VI, SECTION C, LINE 19 990 AVAILABLE UPON REQUEST.